Harry Silvers
Investor Relations, United Therapeutics Corporation
Replay available
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call
United Therapeutics Corporation (NASDAQ: UTHR) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Martine Rothblatt
Chairperson and Chief Executive Officer
Michael Benkowitz
President and Chief Operating Officer
Dr. Leigh Peterson
Executive Vice President of Product Development and Xenotransplantation
Pat Poisson
Executive Vice President of Strategic Development
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for United Therapeutics Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.111 -- 00:00:04.494 Good morning and welcome to the United Therapeutics Corporation second quarter 2026 corporate 00:00:04.494 -- 00:00:08.856 update. My name is JL and I'll be a conference operator today. 00:00:08.856 -- 00:00:13.299 All participants on the call portion of this webcast will be in a listen-only mode until 00:00:13.299 -- 00:00:16.520 the question and answer portion of the earnings call. 00:00:16.520 -- 00:00:20.403 If you'd like to ask a question during this time, simply press star then the number one 00:00:20.403 -- 00:00:24.345 on your telephone keypad. If you'd like to withdraw your question, simply press star 00:00:24.345 -- 00:00:26.286 one again. 00:00:26.286 -- 00:00:28.728 Please note that this call is being recorded. 00:00:28.728 -- 00:00:34.210 I'll now turn the webcast over to Harry Silvers, Investor Relations at United Therapeutics. 00:00:35.011 -- 00:00:39.133 Thank you, JL. Good morning, everyone. It is my pleasure to welcome you to the United 00:00:39.133 -- 00:00:44.536 Therapeutics Corporation's second quarter 2026 corporate update webcast. 00:00:44.536 -- 00:00:48.678 Remarks today will include forward-looking statements representing our expectations or 00:00:48.678 -- 00:00:53.080 beliefs regarding future events. These statements involve risks and uncertainties that 00:00:53.080 -- 00:00:55.953 may cause actual results to differ materially. 00:00:55.953 -- 00:01:01.236 Our latest SEC filings, including forms 10-K and 10-Q, contain additional information 00:01:01.236 -- 00:01:06.619 on these risks and uncertainties. We assume no obligation to update forward-looking statements. 00:01:06.619 -- 00:01:11.001 Today's remarks may discuss the progress and results of clinical trials or other developments 00:01:11.001 -- 00:...